Caladrius Biosciences to Host 2019 Third Quarter Financial Results and Business Update Conference Call on Wednesday, November...
30 October 2019 - 11:30PM
Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the
“Company”), a late-stage therapeutics development biopharmaceutical
company pioneering advancements of cell therapies in select
cardiovascular and autoimmune diseases, announces that the Company
will release financial results for the three and nine months ended
September 30, 2019 after close of the U.S. financial markets on
Wednesday, November 6, 2019.
Caladrius’ management will host a conference call for the
investment community beginning at 4:30 p.m. ET on Wednesday,
November 6, 2019 to discuss the financial results, provide a
company update and answer questions.
Shareholders and other interested parties may participate on the
conference call by dialing (866) 595-8403 (domestic) or (706)
758-9979 (international), using the conference ID number: 9091688.
The conference call will also be webcast live and can be accessed
from the Company’s website at
www.caladrius.com/investors/news-events.
For those unable to participate in the live conference call or
webcast, an audio recording will be available for replay
approximately two hours after the conclusion of the call until
11:59 p.m. ET on November 13, 2019. To access the audio replay,
dial (855) 859-2056 (domestic) or (404) 537-3406 (international)
and provide conference ID number: 9091688
A webcast replay of the conference call will remain available on
the Company’s website for 90 days.
About Caladrius BiosciencesCaladrius is a
late-stage therapeutics development biopharmaceutical company
pioneering advancements of cell therapies for select cardiovascular
and autoimmune diseases. Our leadership team collectively has
decades of biopharmaceutical development experience and
world-recognized scientific achievement in the fields of
cardiovascular and autoimmune disease, among other areas. Our
current product candidates include three developmental treatments
for cardiovascular diseases based on our CD34+ cell therapy
platform: CLBS12, recipient of a SAKIGAKE designation in Japan and
advanced therapy medicinal product classification (ATMP) in Europe,
eligible for early conditional approval for the treatment of
critical limb ischemia in Japan based on an ongoing clinical trial;
CLBS16, subject of the proof-of-concept ESCaPE-CMD clinical trial
in the U.S.A. for the treatment of coronary microvascular
dysfunction; and CLBS14, recipient of a RMAT designation in the
U.S.A. and for which we are in preparation to commence a Phase 3
clinical trial in no option refractory disabling angina. For more
information on the company, please
visit www.caladrius.com.
Contact:
Investors: Caladrius Biosciences, Inc. John Menditto Vice
President, Investor Relations and Corporate Communications
Phone: +1-908-842-0084
Email: jmenditto@caladrius.com
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From Apr 2024 to May 2024
Caladrius Biosciences (NASDAQ:CLBS)
Historical Stock Chart
From May 2023 to May 2024
Real-Time news about Caladrius Biosciences Inc (NASDAQ): 0 recent articles
More News Articles